INT197721
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
CPK elevation was more common in Arm B (45.0% of patients and 12.2% of cycles) than in Arm A (31.6% of patients, 8.4% of cycles). | |||||||||||||||
| |||||||||||||||
|
The second trial is a comparison of prednisolone versus megestrol acetate; those in the megestrol acetate arm did significantly worse [10]. | |||||||||||||||
| |||||||||||||||
|
As a result of this study arm, the speed that the lithium dose may be increased (weekly vs. twice weekly) in children and adolescents will be determined. | |||||||||||||||
| |||||||||||||||
|
Toxicity from skin rash and diarrhea was increased in the erlotinib arm although there were no significant differences for global quality-of-life scores (Moore et al. 2005). | |||||||||||||||
| |||||||||||||||
|
Limitations, including the previously described detection bias for MI [55] and unbalancing of adjunctive therapies following randomization (less platelet IIb/IIIa blockade during cross-over PCI in the conservative arm than in the invasive arm and more oral antiplatelet therapy in the invasive arm) cloud any interpretation of superiority. | |||||||||||||||
| |||||||||||||||
|
Limitations, including the previously described detection bias for MI [55] and unbalancing of adjunctive therapies following randomization (less platelet IIb/IIIa blockade during cross-over PCI in the conservative arm than in the invasive arm and more oral antiplatelet therapy in the invasive arm) cloud any interpretation of superiority. | |||||||||||||||
| |||||||||||||||
|
A superficial vein of the ipsilateral arm was also cannulated for infusion of insulin and glucose (see below). | |||||||||||||||
| |||||||||||||||
|
A priori there is no reason why participants who felt the illusion of ownership to some extent might not also give relatively high scores to these questions: a confusion about the location of the felt touch (Q5), that their arm was virtual (indeed it would be so!) | |||||||||||||||
| |||||||||||||||
|
Of the children classified with nonsevere pneumonia, 13.3% of those in the control arm received early and appropriate treatment with amoxicillin compared to 68.2% of those in the intervention arm, a 5-fold increase in the timely treatment for pneumonia.
| |||||||||||||||
| |||||||||||||||
|
In every BCRL untreated arm, the rates of lymphatic propulsion increased post-treatment as compared to pre-treatment and in 4 of 6 arms, the rates increased during treatment as compared to pre-treatment (Fig. 7A). | |||||||||||||||
| |||||||||||||||
|
70 years) patients.45 However, a recently published phase III trial of GD vs docetaxel alone in elderly patients and subjects with poor performance status showed no survival improvement for the combination arm, suggesting that single agent chemotherapy should remain the standard of care for these groups of patients.46 | |||||||||||||||
| |||||||||||||||
|
In the Spanish study, 135 patients with advanced disease were randomly assigned to cisplatin with etoposide or gemcitabine.14 Despite the lack of a survival benefit, patients treated in the experimental arm reported a significantly higher response rate (40.6% vs 21.9%, P = 0.02) and time to progression (6.9 vs 4.3 months, P = 0.01), with an overall similar toxicity profile. | |||||||||||||||
| |||||||||||||||
|
Lymphocyte subset analysis of the first, randomised therapy phase of the study, showed an increase in CD4 in both arms and an increase in CD8 cells in the placebo arm but a decrease in the active arm (Table 3). | |||||||||||||||
| |||||||||||||||
|
During the first 24 weeks the mean total lymphocyte counts (AUCMB) increased by 148 × 106/L in the placebo arm but decreased by 159 × 106/L in the active arm, a mean difference of 307 × 106/L (SE = 158, p = 0.07) (Table 3). | |||||||||||||||
| |||||||||||||||
|
The first arm included HER2 positive breast cancer patients who were previously treated with trastuzumab and the second arm included advanced HER2 positive breast cancer patients with no prior trastuzumab treatment. | |||||||||||||||
| |||||||||||||||
|
Importantly, patients in the supportive care arm were allowed to cross over to the azacitidine arm after at least 4 months of supportive care or if they met other criteria for worsening disease status prior to that time.9 | |||||||||||||||
| |||||||||||||||
|
Moreover, the results of the BIG 198 study indicate a statistically significant increase in fracture number in the letrozole arm with respect to the tamoxifen arm (9% vs 6%) (Viale et al 2007). | |||||||||||||||
| |||||||||||||||
|
Moreover, the results of the BIG 198 study indicate a statistically significant increase in fracture number in the letrozole arm with respect to the tamoxifen arm (9% vs 6%) (Viale et al 2007). | |||||||||||||||
| |||||||||||||||
|
In a phase III randomized clinical trial of chemo-naive MBC patients coordinated by the Eastern Cooperative Oncology Group (ECOG) E2100, paclitaxel 90 mg/m2 in combination with bevacizumab 10 mg/kg was compared to paclitaxel alone.[23] The patients in the combination arm achieved a significantly longer PFS compared to the paclitaxel monotherapy arm (11.4 months vs 6.11 months) and a significantly increased ORR (30% vs 14%). | |||||||||||||||
| |||||||||||||||
|
In fact in the ATAC trial there was a significant increase in arthralgias in the anastrozole arm when compared to the tamoxifen arm (35.6% vs 29.4%; p < 0.001) (ATAC Trialists Group 2005). | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.